SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is facing intense bearish sentiment and significant volatility as community members aggressively debate the sustainability of its debt-driven Bitcoin acquisition strategy and recent stock dilution. Investors remain deeply divided, with some highlighting the company's leverage as a potential systemic risk, while others view the current price compression as a long-term accumulation opportunity despite the ongoing downward pressure.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is surging following record quarterly revenue and the milestone achievement of positive operating cash flow, signaling a significant transition toward profitability. Investors are actively discussing the company's shift from a pure medical device firm to a semiconductor-based AI imaging platform, with many weighing the impact of its strategic partnership with Midjourney against historical skepticism regarding share offerings and long-term cash burn.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors respond to a series of positive clinical trial results for its next-generation obesity treatment, retatrutide, alongside news of expanded insurance coverage for its core GLP-1 portfolio. The community is actively debating the company's long-term pipeline dominance and its strategic shift into broader therapeutic areas, including infectious disease and oncology, while tracking its momentum toward new record highs.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending as investors focus on the company's strategic position at the intersection of nuclear energy and domestic rare earth supply chains, bolstered by recent government financial support and a push toward independence from foreign critical mineral sources. Community discussion centers on the potential for long-term growth driven by AI-linked power demand, while some investors urge patience as the company executes its mill retooling and finalizes key strategic partnerships.

A composable native asset bridge with unified liquidity and instant guaranteed finality

Stargate

Stargate is gaining attention as community members track its price action and potential recovery from recent volatility. Discussions are heavily focused on the project's role in the DeFi ecosystem, with some investors debating entry points while others analyze its long-term utility and bridge infrastructure.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is seeing intense community debate as investors weigh strong earnings momentum and institutional accumulation against concerns regarding governance, legal investigations, and the broader volatility impacting the fintech sector. The conversation remains highly polarized, with many bulls anticipating a violent short squeeze driven by heavy short interest and positive product expansion, while others focus on technical pullbacks and the risks of a shifting macroeconomic landscape.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing intense selling pressure and retail frustration as the token struggles to maintain support levels, with investors debating whether current price points represent an accumulation opportunity or the bottom of a broader downward trend. Community discussion is heavily focused on the token's lackluster performance compared to other assets, concerns over its long-term viability, and widespread skepticism regarding the impact of upcoming regulatory developments.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is capturing investor attention as the community debates its high-speed AI inference capabilities compared to traditional GPU architectures, with active discussion surrounding upcoming earnings and the potential for new contract announcements. While bulls highlight its strategic growth in the agentic AI market, bears remain cautious about the stock's valuation, insider lock-up periods, and intense competition within the semiconductor space.

BTQ Technologies Corp. engages in the business of post-quantum encryption. Its products include: QCIM, QSSN, OSS, QPoW, QRiNG. The company was founded by Nicolas Roussy Newton on Novemeber 23, 1983 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending as investors react to the launch of a significant at-the-market (ATM) equity program, sparking intense debate between those concerned about share dilution and others viewing it as a necessary step for R&D funding and institutional liquidity. Community sentiment remains polarized, with some bulls emphasizing the firm's long-term potential in quantum-secure infrastructure and possible acquisition interest, while others warn of volatility and technical weakness.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF is trending as investors rotate into defensive, income-focused positions amid market uncertainty, with the community actively discussing its consistent dividend growth and role as a portfolio anchor. Shareholders are heavily focused on dividend reinvestment strategies and are debating the fund's recent performance relative to growth-heavy ETFs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL

FDA accepts RHHBY filing for Lunsumio VELO plus Polivy in relapsed or refractory LBCL as a potential chemotherapy-free treatment option.

JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study

Jazz Pharmaceuticals' Zepzelca fails a phase III lung cancer study, but strong first-line uptake and 2026 guidance remain unchanged.

Novartis Reports Positive Data for Neuromuscular Disorder Drug 

NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a disease-modifying treatment for FSHD.

Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why

PBYI's shares rally 19% in three months as rising Nerlynx demand and a raised 2026 revenue outlook boost investor confidence.

Roche's Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer

RHHBY wins FDA priority review for Tecentriq plus FOLFOX6 in stage III dMMR/MSI-H colon cancer, with a decision due in October 2026.

The $100 Billion Oncology Opportunity Investors are Starting to Notice

Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade. $NTHI, $GSK, $NUVL, $PFE, $RHHBY, $BMY

The Zacks Analyst Blog Highlights Amazon.com, Bank of America, Roche, Oak Valley Bancorp and Ohio Valley Banc

Amazon, Bank of America and Roche are in focus as Zacks highlights growth drivers, expansion plans and product momentum across key businesses.

Top Stock Reports for Amazon, Bank of America & Roche

Amazon's AI push, sales outlook and diversified revenue streams stand out, while Bank of America and Roche navigate growth drivers and key risks.

Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg

Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.

BAYRY or RHHBY: Which Is the Better Value Stock Right Now?

BAYRY vs. RHHBY: Which Stock Is the Better Value Option?

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Roche Holding AG - ADR

NRIX Stock Surges Nearly 70% Premarket Today – Roche And Nurix’s Blood Cancer Drug Collaboration Can Tap A $41B Market

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$1.66	--	--	N/A
Q4 '25	$1.34	--	--	N/A
Q3 '25	$1.37	--	--	N/A
Q2 '25	$1.69	--	--	N/A
Q1 '25	$1.62	--	--	N/A

RHHBYRoche Holdings AG ADR

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest RHHBY News